Biomarker opportunities in the treatment of cancer-related depression

Depression comorbid with cancer is common and associated with a host of negative health outcomes. The inflammatory basis of depression is a growing area of research in cancer, focused on how stressors transduce into inflammation and contribute to the emergence of depression. In this review, we synth...

Full description

Saved in:
Bibliographic Details
Published in:Trends in molecular medicine 2022-12, Vol.28 (12), p.1050-1069
Main Authors: Panjwani, Aliza A., Aguiar, Stefan, Gascon, Bryan, Brooks, David G., Li, Madeline
Format: Article
Language:English
Subjects:
Antidepressive Agents - therapeutic use
Biomarkers - metabolism
cancer
cytokines
depression
Depression - drug therapy
Depression - etiology
Humans
inflammation
Inflammation - drug therapy
Neoplasms - drug therapy
Neoplasms - therapy
pharmacotherapy
Psychotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Depression comorbid with cancer is common and associated with a host of negative health outcomes. The inflammatory basis of depression is a growing area of research in cancer, focused on how stressors transduce into inflammation and contribute to the emergence of depression. In this review, we synthesize inflammatory biomarker associations with both depression and the currently available pharmacotherapies and psychotherapies in cancer, underscoring the need for expanding research on anti-inflammatory agents with antidepressant effects. Modulation of inflammatory neuroimmune pathways can slow tumor progression and reduce metastases. Biomarkers associated with depression in cancer may help with diagnosis and treatment monitoring, as well as inform research on novel drug targets to potentially improve cancer survival. The inflammatory hypothesis of depression holds particular relevance in the context of cancer, where failure to resolve acute inflammation secondary to the physical and psychological stressors of cancer may be the pathophysiological basis for cancer-related depression.Studies profiling changes in inflammatory biomarkers in response to psychological and pharmacological treatments for depression are nascent, but have launched research into the efficacy of anti-inflammatory agents as novel depression treatments in patients with cancer.Neuroimmune pathways linking the stress response to tumor progression provide a biological model for the hypothesis that depression treatment may slow tumor progression and, in turn, improve survival in cancer.
ISSN:1471-4914
1471-499X
DOI:10.1016/j.molmed.2022.10.003